

Non-Alcoholic Steatohepatitis (NASH) - Market Overview by Companies, Drug Profile and Development by Companies 2018

PUNE, MAHARASHTRA, INDIA, March 1, 2018 /EINPresswire.com/ -- Non-Alcoholic Steatohepatitis

Overview

Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.



WISE GUY
REPORTS

AKASH ANAND
ASST.MANAGER - BUSINESS DEVELOPMENT

✉ sales@wiseguyreports.com
☎ Ph: +1-646-843-9312 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>
🐦 <http://twitter.com/WiseGuyReports>
📘 <http://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Non-Alcoholic Steatohepatitis

Click here for sample report @ <https://www.wiseguyreports.com/sample-request/2811463-non-alcoholic-steatohepatitis-nash-pipeline-review-h1-2018>

Top Companies mentioned

AstraZeneca Plc

BASF SE

CymaBay Therapeutics Inc

Daiichi Sankyo Co Ltd

Viking Therapeutics Inc

Zebra Discovery Ltd

Non-Alcoholic Steatohepatitis Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 32, 28, 6, 84, 35 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Non-Alcoholic Steatohepatitis pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Non-Alcoholic Steatohepatitis - Competitive Analysis

Key players are making innovative developments in Non-Alcoholic Steatohepatitis industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis.

The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Non-Alcoholic Steatohepatitis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis.

.Continued

For Detailed Reading Please visit @ <https://www.wiseguyreports.com/reports/2811463-non-alcoholic-steatohepatitis-nash-pipeline-review-h1-2018>

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

NORAH TRENT

+91 841 198 5042

email us here

Wise Guy Reports

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.